Biomarkers in prediction of pulmonary thromboembolism in COVID-19 infection?

Le résumé fourni par la source

Aim This study aimed to investigate whether a biomarker can indicate pulmonary thromboembolism (PTE), which plays a major role in the severity and mortality of COVID-19, at the start of treatment. Materials and Methods A total of 160 adult patients who were admitted to the Chest Diseases Clinic between April 2020 and April 2021 were retrospectively included in this study. The patients were divided into three groups: COVID PCR + PTE + (group 1), COVID PCR – PTE + (group 2), and PCR + PTE – (group 3). Demographic data and biomarker levels, including D-dimer, ferritin, fibrinogen, troponin-I, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), were obtained from the hospital’s electronic data system. Statistical analyses were performed using the STATISTICA 13.0 software package. Results No statistically significant differences were found between the patient groups regarding median age, sex, D-dimer, or troponin-I levels (p>0.05). Statistically significant differences were observed between some groups in ferritin, fibrinogen, CRP, NLR, and PLR values (p<0.05). Conclusion In this study evaluating the potential of biomarkers to indicate pulmonary thromboembolism at the time of diagnosis in SARS-CoV-2 patients, the parameters that showed statistically significant differences were not considered reliable for early detection of PTE, as they may be influenced by multiple factors. Given the limited current data on COVID-19, further studies are needed to clarify these findings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.